Condition: Opioid Use Disorder · Pregnancy Related · Sponsor: Ilana Hull
This study will be a 12-month prospective, genotype-blinded longitudinal observational study with current standard of clinical care. This study will enroll 100 pregnant women with OUD at UPMC Hospitals with its high volumes. Because of the observational nature of the study, the anticipated dropout rate will be ≤ 20%. Investigators expect the effective sample size of evaluable patients will be 200 with longitudinal data.
This description comes directly from the study's public registry record.
Amy Monroe, MPH, MBA · 412-623-6382 · monroeal@upmc.edu
Carly Riedmann, MPH · 412-623-4147 · riedmannca@upmc.edu
Always discuss trial participation with your own doctor first.
| UPMC Magee-Womens Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05942313